A Phase II Study of Gliadel, Concomitant Temozolomide and Radiation, Followed By Dose Dense Therapy With Temozolomide For Newly Diagnosed Malignant High Grade Glioma.

Trial Profile

A Phase II Study of Gliadel, Concomitant Temozolomide and Radiation, Followed By Dose Dense Therapy With Temozolomide For Newly Diagnosed Malignant High Grade Glioma.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Jan 2010

At a glance

  • Drugs Carmustine polifeprosan 20 wafer; Temozolomide
  • Indications Glioma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 22 Jan 2010 Planned end date changed from 1 Dec 2009 to 1 Dec 2010 as reported by ClinicalTrials.gov.
    • 05 Aug 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 27 Jan 2009 Additional lead trial centre identified as reported by ClinicalTrials.gov, last updated 27-Jan-2009
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top